Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1,155
No. of companies carrying out R&D in Biotechnology;250 or more employees;145
No. of companies carrying out R&D in Biotechnology;Total 2021;1,299
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;29.7
%Companies according to biotechnology used: Genetic code;250 or more employees;39.5
%Companies according to biotechnology used: Genetic code;Total 2021;30.8
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;37.4
%Companies according to biotechnology used: Functional units;250 or more employees;46.5
%Companies according to biotechnology used: Functional units;Total 2021;38.4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;20.1
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;33.3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2021;21.5
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;49.2
%Companies according to biotechnology used: Bioprocesses;250 or more employees;63.2
%Companies according to biotechnology used: Bioprocesses;Total 2021;50.8
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7.5
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;15.9
%Companies according to biotechnology used: Sub-cellular organisms;Total 2021;8.5
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;23.7
%Companies according to biotechnology used: Bio-computing;250 or more employees;26.4
%Companies according to biotechnology used: Bio-computing;Total 2021;24.0
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;12.2
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;11.1
%Companies according to biotechnology used: Nanobiotechnology;Total 2021;12.1
%Companies according to biotechnology used: Other;Fewer than 250 employees;17.2
%Companies according to biotechnology used: Other;250 or more employees;14.6
%Companies according to biotechnology used: Other;Total 2021;16.9
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;544
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;15
Companies in which biotechnology activities are: Main and/or exclusive;Total 2021;559
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;191
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;39
Companies in which biotechnology activities are: A secondary line of business;Total 2021;230
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;420
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;90
Companies in which biotechnology activities are: A tool necessary for production;Total 2021;510
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45.9
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;42.3
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2021;45.5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;15.9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;12.5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2021;15.5
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;31.9
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;35.5
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2021;32.3
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24.1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;20.8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2021;23.8
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;16.0
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;12.5
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2021;15.6
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13.9
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;12.5
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2021;13.7
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;9,560
Personnel in R&D in biotechnology (no. of persons);250 or more employees;6,190
Personnel in R&D in biotechnology (no. of persons);Total 2021;15,750
Personnel in R&D in biotechnology (no. of persons): Research personnel;Fewer than 250 employees;5,506
Personnel in R&D in biotechnology (no. of persons): Research personnel;250 or more employees;2,874
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total 2021;8,379
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Fewer than 250 employees;4,055
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;250 or more employees;3,316
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total 2021;7,371
Personnel in R&D in biotechnology (no. of persons). Women;Fewer than 250 employees;4,963
Personnel in R&D in biotechnology (no. of persons). Women;250 or more employees;3,748
Personnel in R&D in biotechnology (no. of persons). Women;Total 2021;8,711
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Fewer than 250 employees;2,838
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;250 or more employees;1,673
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total 2021;4,510
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Fewer than 250 employees;2,125
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;250 or more employees;2,075
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total 2021;4,200
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;6,711.0
Personnel in R&D in biotechnology (FTE);250 or more employees;4,817.6
Personnel in R&D in biotechnology (FTE);Total 2021;11,528.6
Personnel in R&D in biotechnology (FTE): Research personnel;Fewer than 250 employees;4,162.2
Personnel in R&D in biotechnology (FTE): Research personnel;250 or more employees;2,180.5
Personnel in R&D in biotechnology (FTE): Research personnel;Total 2021;6,342.7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Fewer than 250 employees;2,548.8
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;250 or more employees;2,637.1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total 2021;5,185.9
Personnel in R&D in biotechnology (FTE). Women;Fewer than 250 employees;3,575.2
Personnel in R&D in biotechnology (FTE). Women;250 or more employees;2,964.6
Personnel in R&D in biotechnology (FTE). Women;Total 2021;6,539.7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Fewer than 250 employees;2,167.4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;250 or more employees;1,288.4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total 2021;3,455.7
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Fewer than 250 employees;1,407.8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;250 or more employees;1,676.2
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total 2021;3,084.0
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;593,445
Internal expenditure on R&D (thousands of euros);250 or more employees;445,137
Internal expenditure on R&D (thousands of euros);Total 2021;1,038,582
1) By nature of the expense: Current expenses;Fewer than 250 employees;531,987
1) By nature of the expense: Current expenses;250 or more employees;408,103
1) By nature of the expense: Current expenses;Total 2021;940,091
1.1) Remuneration to research personnel;Fewer than 250 employees;194,798
1.1) Remuneration to research personnel;250 or more employees;126,772
1.1) Remuneration to research personnel;Total 2021;321,570
1.2) Remuneration to technical and auxiliary personnel;Fewer than 250 employees;91,565
1.2) Remuneration to technical and auxiliary personnel;250 or more employees;103,271
1.2) Remuneration to technical and auxiliary personnel;Total 2021;194,836
1.3) Other current expenses;Fewer than 250 employees;245,624
1.3) Other current expenses;250 or more employees;178,061
1.3) Other current expenses;Total 2021;423,685
2) By nature of the expense: Capital expenses;Fewer than 250 employees;61,458
2) By nature of the expense: Capital expenses;250 or more employees;37,033
2) By nature of the expense: Capital expenses;Total 2021;98,492
2.1) Land and buildings;Fewer than 250 employees;7,788
2.1) Land and buildings;250 or more employees;2,411
2.1) Land and buildings;Total 2021;10,199
2.2) Equipment and instruments;Fewer than 250 employees;40,235
2.2) Equipment and instruments;250 or more employees;32,349
2.2) Equipment and instruments;Total 2021;72,584
2.3) Acquisition of specific R&D software;Fewer than 250 employees;3,600
2.3) Acquisition of specific R&D software;250 or more employees;2,121
2.3) Acquisition of specific R&D software;Total 2021;5,721
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;9,835
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;152
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2021;9,987
1.1) By origin of the funds: Own funds;Fewer than 250 employees;403,266
1.1) By origin of the funds: Own funds;250 or more employees;308,222
1.1) By origin of the funds: Own funds;Total 2021;711,488
1.2) By origin of the funds: From companies;Fewer than 250 employees;75,949
1.2) By origin of the funds: From companies;250 or more employees;45,789
1.2) By origin of the funds: From companies;Total 2021;121,738
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;76,924
1.3) By origin of the funds: Public Administration funds;250 or more employees;30,552
1.3) By origin of the funds: Public Administration funds;Total 2021;107,477
1.4) By origin of the funds: From Universities;Fewer than 250 employees;192
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total 2021;192
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;1,543
1.5) By origin of the funds: From non profit private institutions;250 or more employees;9,213
1.5) By origin of the funds: From non profit private institutions;Total 2021;10,756
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;35,570
1.6) By origin of the funds: Foreign funds;250 or more employees;51,360
1.6) By origin of the funds: Foreign funds;Total 2021;86,931
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;75,599
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;69,958
Purchase of R&D services in biotechnology (thousands of euros);Total 2021;145,557
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;53,934
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;41,981
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2021;95,915
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;21,665
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;27,977
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2021;49,642
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;42.3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;23.7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2021;40.2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;13.1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;13.9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2021;13.2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;19.4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;16.0
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2021;19.0
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;11.0
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;15.3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2021;11.5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;16.5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;10.4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2021;15.9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17.8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;10.4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2021;17.0
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16.1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;19.5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2021;16.4
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;41.2
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;34.8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2021;40.5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;56.1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;46.5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2021;55.0
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;22.3
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;18.7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2021;21.9
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;24.2
% Companies with income of an international origin related to biotechnological activities;250 or more employees;18.1
% Companies with income of an international origin related to biotechnological activities;Total 2021;23.5
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;10.6
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0.8
% Turnover representing income of an international origin related to biotechnological activities;Total 2021;1.9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;56.0
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;69.8
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2021;61.6
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;44.0
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;30.2
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2021;38.4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;93.8
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;78.7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2021;87.6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;4.9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;19.6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2021;10.9
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;0.6
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;1.8
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2021;1.1
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0.6
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0.0
% Income of an international origin related with activities according to the classification: Other;Total 2021;0.4